Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Current Assets (2023 - 2026)

ArriVent BioPharma has reported Current Assets over the past 4 years, most recently at $348.7 million for Q1 2026.

  • Quarterly results put Current Assets at $348.7 million for Q1 2026, up 87.69% from a year ago — trailing twelve months through Mar 2026 was $348.7 million (up 87.69% YoY), and the annual figure for FY2025 was $332.9 million, up 46.66%.
  • Current Assets reached $348.7 million in Q1 2026 per AVBP's latest filing, up from $332.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $348.7 million in Q1 2026 and bottomed at $160.0 million in Q4 2023.
  • Median Current Assets over the past 4 years was $300.5 million (2024), compared with a mean of $275.4 million.
  • The largest annual shift saw Current Assets plummeted 43.27% in 2025 before it skyrocketed 87.69% in 2026.
  • Over 4 years, Current Assets stood at $160.0 million in 2023, then surged by 41.89% to $227.0 million in 2024, then soared by 46.66% to $332.9 million in 2025, then increased by 4.75% to $348.7 million in 2026.
  • Business Quant data shows Current Assets for AVBP at $348.7 million in Q1 2026, $332.9 million in Q4 2025, and $321.2 million in Q3 2025.